Sol-Gel Technologies (SLGL) EBT Margin (2018 - 2026)
Sol-Gel Technologies (SLGL) posted quarterly EBT Margin of 3569.44% for Q1 2026, up 268981.0% year-over-year from N/an in Q1 2025, and up 140.12% quarter-over-quarter from 8895.83% in Q4 2025.
Sol-Gel Technologies (SLGL) EBT Margin (2018 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has reported EBT Margin for 9 consecutive years, with 3569.44% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT Margin rose 268981.0% year-over-year to 3569.44%; the TTM figure through Mar 2026 stood at 289.71% (up 9319.0% YoY), while the FY2025 annual figure was 340.63%, up 19502.0% from the prior year.
- EBT Margin rose to 3569.44% in Q1 2026 per SLGL's latest filing, from 8895.83% in the prior quarter.
- Across five years, EBT Margin topped out at 3569.44% in Q1 2026 and bottomed at 50899.0% in Q4 2022.
- Historically, EBT Margin has averaged 6287.59% across 5 years, with a median of 1098.82% in 2023.
- Annual changes were most pronounced in 2022 — EBT Margin slumped 5096412 bps — and 2023, when it jumped 3897081 bps.
- Sol-Gel Technologies' EBT Margin stood at 50899.0% in 2022, then soared by 77 bps to 11928.19% in 2023, then slumped by 69 bps to 20103.96% in 2024, then soared by 56 bps to 8895.83% in 2025, then soared by 140 bps to 3569.44% in 2026.
- Business Quant data shows SLGL's EBT Margin at 3569.44% in Q1 2026, 8895.83% in Q4 2025, and 1572.0% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 34.77% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 18.33% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -94.22% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.77% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -2.67% |
| 10 | Sol-Gel Technologies | 240.26 Mn | 230.12 Mn | - | 3,569.44% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3,569.44% |
| Dec 31, 2025 | -8,895.83% |
| Sep 30, 2025 | -1,572.00% |
| Jun 30, 2025 | 62.88% |
| Mar 31, 2025 | 879.63% |
| Dec 31, 2024 | -20,103.96% |
| Sep 30, 2024 | -15.44% |
| Jun 30, 2024 | 24.02% |
| Dec 31, 2023 | -11,928.19% |
| Sep 30, 2023 | -2,961.03% |
| Jun 30, 2023 | -1,098.82% |
| Dec 31, 2022 | -50,899.00% |
| Sep 30, 2022 | -1,388.89% |
| Jun 30, 2022 | 13.16% |
| Mar 31, 2022 | 0.20% |
| Dec 31, 2021 | 65.12% |
| Sep 30, 2021 | 95.21% |
| Jun 30, 2021 | 866.59% |
| Mar 31, 2021 | 602.57% |
| Dec 31, 2020 | -343.17% |